360b-shutterstock-com-sanofi-
360b / Shutterstock.com
12 January 2017Americas

Sanofi and Regeneron’s appeal to suspend Amgen injunction denied

A US district court has denied Sanofi and Regeneron’s motion to suspend an injunction which was obtained by Amgen earlier this month.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
9 January 2017   Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.

More on this story

Americas
9 January 2017   Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.

More on this story

Americas
9 January 2017   Sanofi and Regeneron Pharmaceuticals have revealed plans to appeal against an injunction granted to Amgen, which prevents the companies from selling cholesterol-lowering medicine Praluent.
Americas
6 January 2017   Sanofi and Regeneron Pharmaceuticals must stop selling cholesterol-lowering medicine Praluent after Amgen obtained an injunction against the companies.